AMENDED AND RESTATED ROYALTY REPURCHASE AGREEMENTRoyalty Repurchase Agreement • November 17th, 2011 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This Amended and Restated Royalty Repurchase Agreement (this “Agreement”), dated November 14, 2011, is made by and between Deerfield Private Design Fund II, L.P., a Delaware limited partnership (“Design Fund II”), Deerfield Special Situations Fund, L.P., a Delaware limited partnership (“DSS”), Horizon Santé TTNP SARL, a Luxembourg limited company (“Horizon” and together with Design Fund II and DSS, “Deerfield”) and Titan Pharmaceuticals, Inc., a Delaware corporation (“Titan”).
ROYALTY PURCHASE AGREEMENTRoyalty Purchase Agreement • November 17th, 2011 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This ROYALTY PURCHASE AGREEMENT (this “Agreement”), dated November 14, 2011, is made by and between Deerfield Private Design Fund II, L.P., a Delaware limited partnership (“Design Fund II”), Deerfield Special Situations Fund, L.P., a Delaware limited partnership (“DSS”), Horizon Santé TTNP SARL, a Luxembourg limited company (“Horizon” and together with Design Fund II and DSS, “Deerfield”) and Titan Pharmaceuticals, Inc., a Delaware corporation (“Titan”).
PAYING AGENT AGREEMENTPaying Agent Agreement • November 17th, 2011 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This Paying Agent Agreement is dated as of November 14, 2011 (this “Agreement”) by and among Titan Pharmaceuticals, Inc., a Delaware corporation (“Titan”), Deerfield Management Company, L.P., a Delaware limited partnership (“Deerfield”) and U.S. Bank National Association, as paying agent (the “Paying Agent”).
AMENDED AND RESTATED ROYALTY AGREEMENTAmended and Restated Royalty Agreement • November 17th, 2011 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This AMENDED AND RESTATED ROYALTY AGREEMENT (this “Agreement”), dated November 14, 2011, is made by and between Deerfield Private Design Fund II, L.P., a Delaware limited partnership (“Design Fund II”), Deerfield Special Situations Fund, L.P., a Delaware limited partnership (“DSS”), Horizon Santé TTNP SARL, a Luxembourg limited company (“Horizon” and together with Design Fund II and DSS, “Deerfield”) and Titan Pharmaceuticals, Inc., a Delaware corporation (“Titan”).
ContractAgreement • November 17th, 2011 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances)
AGREEMENT (this “Agreement”), dated as of November 14, 2011, by and among Titan Pharmaceuticals, Inc., a Delaware corporation (“Titan”), Deerfield Private Design Fund II, L.P., a Delaware limited partnership (“DPDF”), Deerfield Private Design International II, L.P., a limited partnership organized under the laws of the British Virgin Islands (“DPDI”), Deerfield Special Situations Fund, L.P., a Delaware limited partnership (“DSS Del.”) and Deerfield Special Situations Fund International Limited, a company organized under the laws of the British Virgin Islands (“DSS BVI” and together with DPDF, DPDI and DSS Del., individually, a “Noteholder” and together, the “Noteholders” and, together with Titan, the “Parties”).
ContractCash Management Agreement • November 17th, 2011 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances)
CASH MANAGEMENT AGREEMENT (this “Agreement”), dated November 14, 2011, by and between Titan Pharmaceuticals, Inc., a Delaware corporation (“Titan”), Deerfield Private Design Fund II, L.P., a Delaware limited partnership (“Design Fund II”), Deerfield Special Situations Fund, L.P., a Delaware limited partnership (“DSS”), and Horizon Sante TTNP SARL, a Luxembourg limited company (“Horizon”) and together with Design Fund II and DSS, the “Purchasers” and, together with Titan, the “Parties”).
